Memory Imaging of Normal Aging - Full Text View

Purpose

The purpose of this study is to develop imaging techniques that can distinguish functional brain changes in people at high risk for dementia years prior to onset of clinical memory problems from those with normal changes of aging.

Condition	Intervention
Alzheimer's Disease	Procedure: BOLD and Perfusion brain MRI


Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Cross-Sectional
Official Title:	BOLD and Perfusion fMRI of Alzheimer's Disease Risk

Resource links provided by NLM:

Genetics Home Reference related topics: Alzheimer disease

MedlinePlus related topics: Alzheimer's Disease Memory

Genetic and Rare Diseases Information Center resources: Familial Alzheimer Disease

U.S. FDA Resources

Further study details as provided by National Institute on Aging (NIA):

Primary Outcome Measures:

identification of consistent patterns of variance in brain function in subjects at risk for Alzheimer's Disease by using APOE ε4 as a marker for disease risk [ Time Frame: single time point ]


Estimated Enrollment:	90
Study Start Date:	August 2005
Study Completion Date:	July 2008
Primary Completion Date:	July 2008 (Final data collection date for primary outcome measure)

Groups/Cohorts	Assigned Interventions
1 Individuals with high risk for Alzheimer's disease	Procedure: BOLD and Perfusion brain MRI Blood oxygenation and perfusion functional MRI performed twice, two weeks apart; each scan lasts 1 hour
2 Individuals with low risk for Alzheimer's disease	Procedure: BOLD and Perfusion brain MRI Blood oxygenation and perfusion functional MRI performed twice, two weeks apart; each scan lasts 1 hour

Detailed Description:

The overall goals of this project are to identify consistent patterns of variance in brain function in patients at risk for Alzheimer's Disease by using APOE ε4 as a marker for disease risk. The activation Blood Oxygen Level Dependency (BOLD) signal will be compared to both resting and activation perfusion signals to assess the variability of cerebral blood flow as it relates to the BOLD signal. Each participant will be imaged on a 3T MRI scanner while performing an associate episodic memory task.

A total of 90 individuals will be recruited for this study. Participants will be non-demented, right handed, adults with or without at least one APOE ε4 allele. Groups will be split as follows: A) ages 25-39: non-ε4 (n=15); B) ages 25-39: +ε4 (n=15); C) ages 40-49: non-ε4 (n=15); D) ages 40-49: +ε4 (n=15);.E) ages 50-65: non-ε4: F) ages 50-65: +ε4 (n=15). These groups will be matched for mean age, mean years of education, gender distribution, as well as the presence or absence of a family history of AD in a first degree relative.

There will be 2 scanning sessions for each participant. Scan session #1 and Scan session #2 will be acquired within 2 weeks of each other and will take approximately one hour each.

Eligibility


Ages Eligible for Study:	25 Years to 65 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

healthy adults from the community

Criteria

Inclusion Criteria:

Right-handed

Exclusion Criteria:

Major medical illnesses
History of significant head trauma with residual cognitive deficits
Other neurological or major psychiatric disorders such as schizophrenia, bipolar disorder, developmental learning disorder, and alcohol or substance abuse
MRI contra-indications

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00315575

Locations


United States, California
Shiley-Marcos Alzheimer's Disease Research Center, University of California, San Diego
La Jolla, California, United States, 92037

Sponsors and Collaborators

National Institute on Aging (NIA)

Investigators


Principal Investigator:	Adam Fleisher, MD	University of California, San Diego

More Information

Publications:

Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-Vance MA, Mazziotta JC, Small GW. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med. 2000 Aug 17;343(7):450-6.

Mayeux R, Ottman R, Tang MX, Noboa-Bauza L, Marder K, Gurland B, Stern Y. Genetic susceptibility and head injury as risk factors for Alzheimer's disease among community-dwelling elderly persons and their first-degree relatives. Ann Neurol. 1993 May;33(5):494-501.

Fleisher AS, Houston WS, Eyler LT, Frye S, Jenkins C, Thal LJ, Bondi MW. Identification of Alzheimer disease risk by functional magnetic resonance imaging. Arch Neurol. 2005 Dec;62(12):1881-8.

Fleisher A, Grundman M, Jack CR Jr, Petersen RC, Taylor C, Kim HT, Schiller DH, Bagwell V, Sencakova D, Weiner MF, DeCarli C, DeKosky ST, van Dyck CH, Thal LJ; Alzheimer's Disease Cooperative Study. Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. Arch Neurol. 2005 Jun;62(6):953-7.


Responsible Party:	Adam Fleisher, MD, University of California, San Diego
ClinicalTrials.gov Identifier:	NCT00315575 History of Changes
Other Study ID Numbers:	IA0092 5K23AG024062-02 ( U.S. NIH Grant/Contract )
Study First Received:	April 14, 2006
Last Updated:	January 22, 2009

Keywords provided by National Institute on Aging (NIA):


Dementia brain circulation disease /disorder proneness /risk neuropathology neurophysiology aging	apolipoprotein E genotype hemodynamics memory temporal lobe /cortex

Additional relevant MeSH terms:


Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases	Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders

ClinicalTrials.gov processed this record on July 19, 2017